Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 14c

November 9, 2016 7:06 AM EST

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.70), $0.14 better than the analyst estimate of ($0.84). Revenue for the quarter came in at $4.36 thousand versus the consensus estimate of $50 thousand.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities

The Children's Investment Fund (TCI), Earnings